An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

Anti-angiogenesis drugs Lucentis and Eylea have proved game changers in the treatment of wet age-related macular degeneration, but to stave off AMD blindness, patients must submit every four to eight weeks for the rest of their lives to costly, painful, and potentially dangerous injections in the eyeball. Avalanche Biotechnologies Inc. hopes to replace that chronic regimen with just a single therapeutic gene injection that will set what it describes as an ocular protein factory into production that will stave off AMD pathology long term.